These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
2 files

Antibody Screening Results for Anti-Nucleocapsid Antibodies Towards the Development of a SARS-CoV-2 Nucleocapsid Protein Antigen Detecting Lateral Flow Assay

revised on 09.01.2021, 04:47 and posted on 11.01.2021, 09:33 by David Cate, Helen Hsieh, Veronika Glukhova, Joshua D Bishop, H Gleda Hermansky, Brianda Barrios-Lopez, Ben D Grant, Caitlin E Anderson, Ethan Spencer, Samantha Kuhn, Ryan Gallagher, Rafael Rivera, Crissa Bennett, Sam A Byrnes, John T Connelly, Puneet K Dewan, David S. Boyle, Bernhard H Weigl, Kevin P Nichols

The global COVID-19 pandemic has created an urgent demand for large numbers of inexpensive, accurate, rapid, point-of-care diagnostic tests. Analyte-based assays are suitably inexpensive and can be rapidly mass-produced, but for sufficiently accurate performance they require highly optimized antibodies and assay conditions. We used an automated liquid handling system, customized to handle arrays of lateral flow immunoassay (LFA) tests in a high-throughput screen, to identify anti-nucleocapsid antibodies that will perform optimally in an LFA. We tested 1021 anti-nucleocapsid antibody pairs as LFA capture and detection reagents with the goal of highlighting pairs that have the greatest affinity for unique epitopes of the nucleocapsid protein of SARS-CoV-2 within the LFA format. In contrast to traditional antibody screening methods (e.g., ELISA, bio-layer interferometry), the method described here integrates real-time reaction kinetics with transport in, and immobilization directly onto, nitrocellulose. We have identified several candidate antibody pairs that are suitable for further development of an LFA for SARS-CoV-2.


Funding provided by The Global Good Fund and Global Health Labs, a nonprofit organization created by Gates Ventures and the Gates Foundation to develop innovative solutions to address unmet needs in primary health care centers and the last mile.


Email Address of Submitting Author


Global Health Labs


United States of America

ORCID For Submitting Author


Declaration of Conflict of Interest

No conflict of interest